Ginger Capsules for the Prophylactic Treatment of Migraine

Double-blind Placebo-controlled Clinical Trial of Ginger (Zingiber Officinale) in Prophylactic Migraine Treatment

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02570633

Enrollment

107

Registered

2015-10-07

Start date

2015-04-30

Completion date

2016-11-30

Last updated

2020-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine

Keywords

Migraine, Ginger, Prophylactic treatment

Brief summary

The main objective of the study is to evaluate ginger efficacy as an prophylactic treatment of migraine.

Detailed description

Patients with the diagnosis of migraine according to the IHS criteria will receive capsules of 200 mg of ginger extract (5% active ingredient) or placebo (cellulose) to be taken three times a day for 12 weeks.

Interventions

OTHERExtract of ginger

Migraine patients (both genders) will receive capsules of 200 mg of ginger extract (5% gingerols) to be taken three times a day for 12 weeks.

OTHERCellulose

Migraine patients (both genders) will receive capsules of 200 mg of placebo (cellulose) to be taken three times a day for 12 weeks.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

* Aged between 18 and 60 years old; * Migraine diagnosis; * Agree to sign the informed consent.

Exclusion criteria

* Patients with headaches not characterized as migraine; * Pregnant or lactating women; * Fertile and sexually active women who do not use contraception; * Abuse of painkillers, alcohol or other drugs; * People with hypersensitivity to ginger compounds; * People with severe neurological diseases (e.g. epilepsy) * People in use of anticoagulant drugs.

Design outcomes

Primary

Measure	Time frame	Description
Change in the frequency of migraine attacks.	12 weeks	Frequency of migraine attacks will be assessed by headache diary.

Secondary

Measure	Time frame	Description
Change in migraine impact in the last month.	4 weeks	Migraine impact will be assessed by HIT-6.
Change in migraine impact in the last three months.	12 weeks	Migraine impact will be assessed by MIDAS.
Changes in the serum levels of biomarkers.	12 weeks	Biomarkers: inflammatory mediators and neurotrophic factors
Changes in Resting Energy Expenditure	4, 8 and 12 weeks	Resting Energy Expenditure will be assessed by calorimeter

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 20, 2026